Home › NDC Lookup › RxCUI directory › RxCUI 351992

Oxcarbazepine 60 MG/ML Oral Suspension [Trileptal] — RxCUI 351992

Name: Oxcarbazepine 60 MG/ML Oral Suspension [Trileptal] (RxCUI 351992)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 351992 Semantic branded drug · SBD ● Current RxNorm concept 4 FDA products 7 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI351992

Official nameOxcarbazepine 60 MG/ML Oral Suspension [Trileptal]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asTrileptal 60 MG/ML Oral Suspension; Trileptal 300 MG in 5 mL Oral Suspension; Trileptal 300 MG per 5 ML Oral Suspension

FDA products mapped4

Package NDCs mapped7

Reported Medicaid activity (SDUD)52,318 prescriptions · 40 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Oxcarbazepine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

It treats partial-onset seizures, which start in one area of the brain. Depending on the product and your age, it may be used alone or along with other seizure medicines. Your phar...
Take it by mouth exactly as prescribed. Immediate-release tablets and the suspension are usually taken twice a day, with or without food. Extended-release products like Oxtellar XR...
Dizziness, sleepiness, tiredness, double vision, nausea, headache, and unsteadiness are the most common. Be careful driving until you know how it affects you. Tell your doctor if t...
Call for any new rash, blistering, or peeling skin, or swelling of the face, lips, or throat. Also call for confusion, severe headache or nausea, more seizures, or mood changes and...

📖 Read our full Oxcarbazepine guide →

🕸️ Concept Web — How Oxcarbazepine 60 MG/ML Oral Suspension [Trilepta... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Oxcarbazepine 60 MG/ML Oral Suspension [Trileptal] RxCUI 351992 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Oxcarbazepine 32624 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Trileptal 261680 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Oxcarbazepine Oral Suspension 375197 SCDF
- Oxcarbazepine Oral Liquid Product 1160128 SCDG
- Oxcarbazepine Oral Product 1160129 SCDG
- Oxcarbazepine Oral Suspension [Trileptal] 365857 SBDF
- Trileptal Oral Liquid Product 1183778 SBDG
- Trileptal Oral Product 1183779 SBDG
- Oral Suspension 316969 DF
- Oral Liquid Product 1151137 DFG
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Oxcarbazepine 60 MG/ML Oral Suspension 283536 SCD
- Oxcarbazepine 60 MG/ML 332278 SCDC
- Oxcarbazepine 60 MG/ML [Trileptal] 575736 SBDC

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Oxcarbazepine 60 MG/ML Oral Suspension SCD · 283536
Oxcarbazepine 60 MG/ML SCDC · 332278
Oxcarbazepine Oral Suspension SCDF · 375197
Oxcarbazepine Oral Liquid Product SCDG · 1160128
Oxcarbazepine Oral Product SCDG · 1160129

Brand-Name Concepts

Oxcarbazepine 60 MG/ML [Trileptal] SBDC · 575736
Oxcarbazepine Oral Suspension [Trileptal] SBDF · 365857
Trileptal Oral Liquid Product SBDG · 1183778
Trileptal Oral Product SBDG · 1183779
Trileptal BN · 261680

📦 FDA Products & Package NDCs

4 products · 7 package NDCs

7 package NDCs map to RxCUI 351992 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00078-0337-05	100 TABLET, FILM COATED in 1 BOTTLE (0078-0337-05)	Trileptal	Novartis Pharmaceuticals Corporation	2000-01-30
00078-0337-06	100 BLISTER PACK in 1 BOX, UNIT-DOSE (0078-0337-06) / 1 TAB...	Trileptal	Novartis Pharmaceuticals Corporation	2000-01-30
00078-0357-52	250 mL in 1 BOTTLE (0078-0357-52)	Trileptal	Novartis Pharmaceuticals Corporation	2001-05-30
00078-0456-05	100 TABLET, FILM COATED in 1 BOTTLE (0078-0456-05)	Trileptal	Novartis Pharmaceuticals Corporation	2000-01-30
00078-0456-35	100 BLISTER PACK in 1 BOX, UNIT-DOSE (0078-0456-35) / 1 TAB...	Trileptal	Novartis Pharmaceuticals Corporation	2000-01-30
00078-0457-05	100 TABLET, FILM COATED in 1 BOTTLE (0078-0457-05)	Trileptal	Novartis Pharmaceuticals Corporation	2000-01-30
00078-0457-35	100 BLISTER PACK in 1 BOX, UNIT-DOSE (0078-0457-35) / 1 TAB...	Trileptal	Novartis Pharmaceuticals Corporation	2000-01-30

Observed labelers: Novartis Pharmaceuticals Corporation (7) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.